Versant Capital Management’s Chiron Real Estate Inc XRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.67K Hold
151
﹤0.01% 2408
2026
Q1
$5K Hold
151
﹤0.01% 2380
2025
Q4
$5.09K Sell
151
-414
-73% -$13.5K ﹤0.01% 2249
2025
Q3
$19K Sell
565
-2
-0.4% -$71 ﹤0.01% 1605
2025
Q2
$19.6K Buy
567
+257
+83% +$8.95K ﹤0.01% 1543
2025
Q1
$13.6K Buy
310
+117
+61% +$4.83K ﹤0.01% 1559
2024
Q4
$7.45K Buy
193
+165
+589% +$7.3K ﹤0.01% 1554
2024
Q3
$1.38K Buy
28
+23
+460% +$1.08K ﹤0.01% 1668
2024
Q2
$245 Hold
5
﹤0.01% 1883
2024
Q1
$236 Hold
5
﹤0.01% 1818
2023
Q4
$300 Hold
5
﹤0.01% 1792
2023
Q3
$242 Hold
5
﹤0.01% 1843
2023
Q2
$247 Hold
5
﹤0.01% 1967
2023
Q1
$241 Hold
5
﹤0.01% 1699
2022
Q4
$256 Sell
5
-16
-76% -$724 ﹤0.01% 1561
2022
Q3
$1K Buy
21
+17
+425% +$938 ﹤0.01% 1234
2022
Q2
$0 Buy
+4
New +$269 ﹤0.01% 1521

Other funds holding XRN

Versant Capital Management's XRN Position: Q2 2026 in Review

Versant Capital Management held its Chiron Real Estate Inc (XRN) position steady in Q2 2026 at 151 shares worth $5.67K. The position accounts for ﹤0.01% of the portfolio, ranked #2408.

Versant Capital Management first reported a position in XRN in Q2 2022 and has held it in 17 quarters since. The position peaked at $19.6K in Q2 2025. 170 funds tracked by Wall St. Rank hold XRN as of Q2 2026.

  • Versant Capital Management held 151 shares of Chiron Real Estate Inc worth $5.67K as of Q2 2026.
  • Versant Capital Management left its Chiron Real Estate Inc share count unchanged in Q2 2026.
  • Chiron Real Estate Inc made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2408 holding.
  • Versant Capital Management first reported a position in Chiron Real Estate Inc in Q2 2022 and has held it in 17 quarters since.
  • Versant Capital Management's Chiron Real Estate Inc position peaked at $19.6K in Q2 2025.
  • 170 funds tracked by Wall St. Rank held Chiron Real Estate Inc as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.